Xilio Therapeutics, Inc.
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer. Its pipeline includes masked antibody-based therapies and other engineered biologics designed to activate in the tumor microenvironment, with development conducted through its wholly owned subsidiary, Xilio Development, Inc.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEngineered IL-12-based oncology programs designed to activate in tumors.
Conditionally activated T cell engager molecules for cancer targets.
Antibody therapeutics designed to reduce systemic activity and improve selectivity.
Partnered discovery, development, and option agreements with pharma collaborators.
Customers
Xilio’s direct counterparties are pharmaceutical partners rather than end patients, since the company monetizes its science through collaborations, licenses, and option agreements. Its programs are aimed at oncology drug developers seeking differentiated immunotherapy assets that can be advanced into clinical development and commercialization. In the longer term, if products are approved, the ultimate end customers would be cancer patients treated through hospitals and oncology centers.
Companies such as Gilead and AbbVie that license or option Xilio programs for development and commercialization.
Hospitals, investigators, and trial networks that support testing of Xilio’s oncology candidates.
Hospitals and cancer centers that would use approved therapies if any candidates reach market.
Strategy
Xilio’s strategy is to advance tumor-activated immunotherapy assets while using partnerships to share development risk and extend reach. The company is prioritizing collaboration structures, option deals, and licensing transactions that can fund research while preserving upside in its pipeline. Its long-term position depends on generating clinical proof of concept and converting platform science into partnered or approved oncology products.
Partnerships provide funding, validation, and commercialization reach for early-stage assets.
Clinical and preclinical progress is needed to create value and attract partners or approvals.
Early-stage biotech development requires external financing before product revenue exists.
Geography
Xilio is headquartered in the United States and conducts its corporate and research activities from there. Its business model is global in scope because its collaboration agreements grant worldwide development and commercialization rights to partners, even though the company itself is still centered in U.S.-based operations.
Risks
Xilio is exposed to the execution risk typical of early-stage biotech companies: its programs may fail in preclinical or clinical development, and partners may not prioritize or continue development. The company also depends on external capital and collaboration economics, so financing availability, dilution, and partner decision-making can materially affect its ability to progress the pipeline.
- Financing and going-concern riskImpact: CriticalLikelihood: High
The company needs substantial additional capital before product revenue is available.
Exposure - Clinical development failureImpact: HighLikelihood: High
Early-stage oncology candidates may not show sufficient safety or efficacy.
Exposure: Preclinical and clinical pipeline
- Partner dependence and limited control over partnered programsImpact: HighLikelihood: Medium
Collaborators can decide whether and how quickly to advance licensed assets, affecting timing and value capture.
Exposure - Competitive pressure in oncology immunotherapyImpact: MediumLikelihood: Medium
Larger pharma and biotech firms may develop similar or superior therapies faster.
Exposure
Accounting
Judgemental itemsChanges in valuation assumptions can create non-cash gains or losses that affect reported results.
Impact: Common stock warrant liabilities
Upfront fees, option payments, and milestones require judgment on performance obligations and timing.
Impact: Revenue and deferred revenue
Clinical, manufacturing, and external development costs must be accrued based on estimates.
Impact: Operating expenses
Cash runway assumptions influence disclosure and investor interpretation of liquidity risk.
Impact: Liquidity disclosures
Similar listed companies
Publicly listed companies with a comparable business focus.
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Elicio Therapeutics, Inc.
ELTX · Pharmaceutical Preparations
Phio Pharmaceuticals Corp.
PHIO · Pharmaceutical Preparations
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026